Registration, insurance, and medical application of biotechnological drugs in Russia

Abstract

Existing approaches to the registration, insurance, and application of biotechnological drugs in Russia were analyzed using monoclonal antibody drugs and those produced using recombinant DNAtechnology as examples. Pharmacoeconomic aspects of using these drugs in the RF were described and compared with WHO recommendations for their use. © 2013 Springer Science+Business Media New York.